Febuxostat Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-R-0012

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents4
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued Solicitation SPE2D2-26-R-0012 for the procurement of Febuxostat Tablets. This solicitation seeks qualified contractors capable of manufacturing and supplying pharmaceutical-grade Febuxostat Tablets, aligning with the agency’s ongoing commitment to ensuring the availability of critical medical supplies for military and federal healthcare operations. The scope of this procurement encompasses the manufacturing, packaging, and delivery of Febuxostat Tablets, a medication commonly used in the management of chronic gout and hyperuricemia. The intended outcome is to secure a reliable supply chain for this essential pharmaceutical product, supporting the health and readiness of service members and other beneficiaries served by DLA Troop Support. Key requirements for this solicitation include compliance with the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing. Contractors must demonstrate the capability to meet stringent quality standards and regulatory requirements associated with pharmaceutical production, as outlined by federal guidelines. The Product Service Code (PSC) for this requirement is 6505, further specifying the focus on drugs and biologicals. The contracting activity is managed by DLA Troop Support, a federal office within the Defense Logistics Agency. Interested parties may direct inquiries to the primary point of contact, Christopher Newman ([email protected], 445-737-7371), or the secondary contact, Jason C. Wray ([email protected], 445-737-6304), for further clarification regarding solicitation details or submission procedures. This opportunity is classified as a solicitation, indicating that the government is actively seeking proposals from qualified vendors. The notice does not specify any set-aside requirements or special considerations such as small business preferences; interested contractors should review the solicitation documents for any additional eligibility criteria or evaluation factors. The solicitation was posted on October 14, 2026, with responses due by October 15, 2026. All relevant attachments and further details can be accessed via the official SAM.gov opportunity page (https://sam.gov/opp/fb0d82ac31db4a84863e0514b04057eb/view). Contractors with proven experience in pharmaceutical preparation manufacturing, particularly those with the capacity to produce and deliver Febuxostat Tablets in accordance with federal standards, are encouraged to review the solicitation documents and consider submitting a proposal. This procurement represents a stable and mission-critical requirement, with expectations for consistent quality, regulatory compliance, and timely delivery throughout the contract lifecycle.